{"id":5716,"date":"2024-05-14T08:49:19","date_gmt":"2024-05-14T13:49:19","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5716"},"modified":"2025-06-27T11:17:42","modified_gmt":"2025-06-27T16:17:42","slug":"nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/05\/14\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\/","title":{"rendered":"Nanoscope Therapeutics nombra a Khandan Baradaran vicepresidente senior de reglamentaci\u00f3n y calidad"},"content":{"rendered":"
\n
\n
<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n

DALLAS, TX (14 de mayo de 2024) \u2013 Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda cl\u00ednica en etapa avanzada que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina y degeneraciones maculares relacionadas con la edad (DMAE), anunci\u00f3 hoy el nombramiento de Khandan Baradaran, PhD, como vicepresidente senior de Regulaci\u00f3n y Calidad. El Dr. Baradaran aporta casi dos d\u00e9cadas de amplia experiencia en la fabricaci\u00f3n y revisi\u00f3n regulatoria de productos de terapia g\u00e9nica, incluida la experiencia regulatoria en Qu\u00edmica, Fabricaci\u00f3n y Controles (CMC).<\/p>\n

\u201cLa experiencia de Khandan liderando la calidad y el cumplimiento de las compa\u00f1\u00edas biofarmac\u00e9uticas de enfermedades gen\u00e9ticas raras ser\u00e1 valiosa a medida que continuamos avanzando en nuestra vers\u00e1til plataforma MCO, incluida MCO-010, que est\u00e1 impulsando nuestra creciente cartera de programas. Este nombramiento respalda el avance continuo de nuestras terapias independientes de las mutaciones para restaurar la visi\u00f3n en millones de personas ciegas por enfermedades de la retina y destaca nuestro crecimiento continuo como empresa\u201d, dijo Sulagna Bhattacharya, cofundadora y directora ejecutiva de Nanoscope.<\/p>\n

\u201cMe siento honrado de unirme al equipo altamente motivado de Nanoscope en el desarrollo de su novedoso enfoque para el tratamiento de enfermedades degenerativas de la retina\u201d, declar\u00f3 el Dr. Baradaran. \u201cTras los impresionantes resultados de eficacia y seguridad duraderos del ensayo cl\u00ednico aleatorizado y controlado en retinosis pigmentaria (RP), espero con entusiasmo contribuir al avance de Nanoscope a medida que superamos los pr\u00f3ximos hitos regulatorios y nos preparamos para su comercializaci\u00f3n\u201d.\u201d<\/p>\n

El Dr. Baradaran fue recientemente vicepresidente de CMC regulatorio en Ultragenyx Pharmaceutical Inc., una compa\u00f1\u00eda biofarmac\u00e9utica involucrada en la investigaci\u00f3n y el desarrollo de nuevos productos para el tratamiento de enfermedades gen\u00e9ticas raras y ultrararas. Anteriormente, el Dr. Baradaran fue vicepresidente y director de calidad de Dimension Therapeutics, una empresa de terapia g\u00e9nica centrada en el desarrollo de tratamientos novedosos para enfermedades raras. Antes de esto, ocup\u00f3 puestos regulatorios y de CMC en Biogen, Novartis y Dyax. Tiene un doctorado en Virolog\u00eda de la Universidad de Harvard y una licenciatura en Biolog\u00eda Molecular del Wellesley College.<\/p>\n

Acerca de Nanoscope Therapeutics Inc.
\n<\/strong>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas gen\u00e9ticamente independientes que restauran la vista para los millones de pacientes cegados por enfermedades hereditarias de la retina, para las cuales no existe cura. El principal activo de la empresa, MCO-010, anunci\u00f3 recientemente los datos de 100 semanas de<\/a> el ensayo cl\u00ednico RESTORE Fase 2b\/3 multic\u00e9ntrico, aleatorizado, doble enmascarado y controlado de forma simulada en los EE. UU. para RP (NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con enfermedad de Stargardt (NCT05417126<\/a> ). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la RP como para la enfermedad de Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para atrofias geogr\u00e1ficas secundarias a la DMAE.<\/p>\n

Contacto de inversores:<\/strong>
\nSocios Argot
\n212-600-1902
\nPR@nanostherapeutics.com<\/a><\/p>\n

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"

DALLAS, TX (May 14, 2024) \u2014 Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced the appointment of Khandan Baradaran, PhD, as Senior Vice President of Regulatory and Quality. Dr. Baradaran brings nearly two decades of extensive experience in manufacturing and regulatory […]<\/p>\n","protected":false},"author":6,"featured_media":5720,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5716","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/05\/14\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/05\/14\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-14T13:49:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:17:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_KhandanB_V2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_KhandanB_V2.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/14\\\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/14\\\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality\",\"datePublished\":\"2024-05-14T13:49:19+00:00\",\"dateModified\":\"2025-06-27T16:17:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/14\\\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\\\/\"},\"wordCount\":424,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/14\\\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/NSCOPE_LI_KhandanB_V2.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/14\\\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/14\\\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\\\/\",\"name\":\"Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/14\\\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/14\\\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/NSCOPE_LI_KhandanB_V2.jpg\",\"datePublished\":\"2024-05-14T13:49:19+00:00\",\"dateModified\":\"2025-06-27T16:17:42+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/14\\\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/14\\\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/14\\\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/NSCOPE_LI_KhandanB_V2.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/NSCOPE_LI_KhandanB_V2.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/14\\\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics nombra a Khandan Baradaran como Vicepresidente S\u00e9nior de Asuntos Regulatorios y Calidad - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/05\/14\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/05\/14\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-05-14T13:49:19+00:00","article_modified_time":"2025-06-27T16:17:42+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_KhandanB_V2.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_KhandanB_V2.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/05\/14\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/14\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality","datePublished":"2024-05-14T13:49:19+00:00","dateModified":"2025-06-27T16:17:42+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/14\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\/"},"wordCount":424,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/14\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_KhandanB_V2.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/05\/14\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\/","url":"https:\/\/nanostherapeutics.com\/2024\/05\/14\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\/","name":"Nanoscope Therapeutics nombra a Khandan Baradaran como Vicepresidente S\u00e9nior de Asuntos Regulatorios y Calidad - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/14\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/14\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_KhandanB_V2.jpg","datePublished":"2024-05-14T13:49:19+00:00","dateModified":"2025-06-27T16:17:42+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/14\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/05\/14\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/05\/14\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_KhandanB_V2.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_KhandanB_V2.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/05\/14\/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5716"}],"version-history":[{"count":3,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5716\/revisions"}],"predecessor-version":[{"id":9045,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5716\/revisions\/9045"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5720"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5716"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5716"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}